Bladder cancer

This analysis revealed RNA marker candidates reflecting coding sequences, non-coding sequences, and circular RNAs. Next, they designed and validated PCR amplicons for a set of novel marker candidates and tested them in human bladder…

Patients with non-invasive, low-risk bladder cancer have no further treatment rather than surgery and regular cystoscopies (camera is passed through the urethra into the bladder to check for further tumors). The present study utilized…

show that particular cancer DNA marker in blood of patients with urothelial cancer following surgery to remove their tumour has a higher likelihood of cancer relapse. These patients also benefit from subsequent atezolizumab…

MELBOURNE, Australia, June 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed in a Phase I study of TLX250-CDx (89Zr-DFO-girentuximab) in…

TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of innovative…

To evaluate for benefit, patients were randomized to receive either nivolumab or a placebo every two weeks for one year. Patients and physicians were blinded to the treatment. Both safety and quality of life were evaluated. Dr.…

Adding an immune checkpoint inhibitor to first-line platinum-based chemotherapy was not associated with clear survival benefits in advanced…

Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial…

A multivariate analysis revealed that non-BCG treatment was an independent risk factor for recurrence, and a higher De Ritis ratio was an independent risk factor for cancer progression. Dr. Takashi Kawahara from The Yokohama City…